Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAAT3 | P53816 | 1/20 | 0.51 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.51 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.51 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11356452 | 0.98 | TDP1 (0.50) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| Water SCHEMBL28390285 | 0.98 | TDP1 (0.50) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| Methyl Alcohol SCHEMBL28046580 | 0.98 | TDP1 (0.50) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| SCHEMBL4375147 | 0.98 | TDP1 (0.50) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| Hydrochloric Acid SCHEMBL1421839 | 0.98 | TDP1 (0.50) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| SCHEMBL11357520 | 0.98 | TDP1 (0.50) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| SCHEMBL4367534 | 0.98 | TDP1 (0.50) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| Alcohol SCHEMBL29199086 | 0.94 | TDP1 (0.48) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| SCHEMBL660116 | 0.94 | IGF1R (0.52) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 | |
| SCHEMBL20330088 | 0.92 | NAAA (0.52) | PLAAT3PLAAT5PLAAT2PLAAT4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117903018-A | Preparation method of tolbutamide crystal | 内蒙古科技大学 | 2024-04-19 | — | — | CN | claimed |
| CN-104788350-A | Method for acquiring medicinally-advantageous crystal form of tolbutamide through rapid cooling and crystallization | UNIV TIANJIN | 2015-07-22 | — | — | CN | claimed |
| EP-0853618-B1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL -AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMA INC (US) | 2011-08-17 | — | — | EP | claimed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| EP-1660507-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| WO-2005021558-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20240368209-A1 | GEMCITABINE ANTICANCER DERIVATIVE AND ANTICANCER PHARMACEUTICAL USE | ASCENTAWITS PHARMACEUTICALS, LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4365182-A1 | GEMCITABINE ANTICANCER DERIVATIVE AND ANTICANCER PHARMACEUTICAL USE | Ascentawits Pharmaceuticals, Ltd. (CN) | 2024-05-08 | — | — | EP | disclosed |
| US-11739076-B2 | Compound or its salt thereof targeting fibroblast activation protein, its preparation methods and its uses thereof | INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, R.O.C. (TW) | 2023-08-29 | — | — | US | disclosed |
| CN-113943717-B | CYP2C9 mutant, corresponding nucleic acid segment and application thereof | 北京医院 | 2023-08-08 | — | — | CN | disclosed |
| CN-1368879-A | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for the treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia | METABOLEX INC (US) | 2002-09-11 | — | — | CN | disclosed |
| WO-2002044113-A2 | USE OF(-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDEMIA AND HYPERURICEMIA | METABOLEX, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-1183020-A2 | USE OF(-)(3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL)ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA | METABOLEX, INC. (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6262118-B1 | THERAPY OF TYPE 2 DIABETES IN A MAMMAL BY ADMINISTERING (-) 4-CHLOROPHENYL-(3-TRIFLUOROMETHYLPHENOXY)ACETIC ACID DERIVATIVE | METABOLEX, INC. | 2001-07-17 | — | — | US | disclosed |
| WO-2000074666-A2 | USE OF (-) (3-TRIHALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES, HYPERLIPIDAEMIA AND HYPERURICAEMIA | METABOLEX, INC. (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | PLAAT3 3104/4885PLAAT5 1911/4885PLAAT2 2980/4885 |
| US-11739076-B2 | Compound or its salt thereof targeting fibroblast activation protein, its preparation methods and its uses thereof | FIBP, FGFR2, FGFR1 | PLAAT3 269/4885PLAAT5 564/4885PLAAT2 436/4885 |
| US-20240368209-A1 | GEMCITABINE ANTICANCER DERIVATIVE AND ANTICANCER PHARMACEUTICAL USE | AKR1C3, AKR1C2, AKR1A1 | PLAAT3 140/4885PLAAT5 1039/4885PLAAT2 1149/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | PLAAT3 3104/4885PLAAT5 1911/4885PLAAT2 2980/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | PLAAT3 3104/4885PLAAT5 1911/4885PLAAT2 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.